IPCA Laboratories Limited announced the outcome of its Board Meeting held on January 13, 2026. The Board approved the sale of 100% shareholding of the company's wholly-owned step-down subsidiary, Bayshore Pharmaceuticals LLC, USA, to Centaur Pharmaceuticals USA Inc. for a consideration of USD 4,00,000 (four lacs only).

Bayshore Pharmaceuticals LLC, previously engaged in the generic pharmaceuticals marketing and distribution business in the USA, had its business operations and product approvals sold to Unichem Pharmaceuticals (USA) Inc. and Unichem Laboratories Ltd. respectively in September 2024. Post these transactions, Bayshore has no ongoing business, assets, or liabilities, except for a minimal share capital and a small bank balance.

The sale of Bayshore's entire shareholding is subject to necessary due diligence and approvals. The agreement for sale is expected to be entered into around January 20, 2026, with completion anticipated within 30 days thereafter. The buyer, Centaur Pharmaceuticals USA Inc., is an unrelated party.

Additionally, the Board discussed and proposed to update the company's registered office address to include the district details (Mumbai) on the MCA website via Form INC-22. This update is necessary for filing online Industrial Entrepreneur Memorandum (IEM) applications for new industrial projects through the National Single Window System (NSWS) Portal, as the current MCA master data lacks the district information for the registered office.

The Board Meeting commenced at 10:15 am and concluded at 10:35 am.